The company has a strong market position in the NCB-based specialty chemicals segment. In Q2 FY26, the company demonstrated robust financial growth with a 21% revenue increase and 150% rise in Profit After Tax, with strategic initiatives underway to diversify markets and enhance capacity, particularly in the MMA segment. The company combines process chemistry expertise with scale-up engineering competence to serve downstream pharmaceutical, agricultural, and industrial customers.
Cyborg Score Rationale
Net profit jumped 189% in Q3 2025-2026, reaching ₹133 crore, demonstrating strong earnings momentum. UBS upgraded the stock from Sell to Buy, raising target price from ₹615 to ₹625, signaling improving sentiment. However, the company faces headwinds from U.S. tariffs on chemical exports and maintains modest historical revenue growth.
Top Insights
U.S. tariffs on Indian chemical exports are pressuring margins and competitiveness, requiring strategic market diversification
Recently secured long-term Methanol and Toluene supply contracts from GCC and Southeast Asia to ensure supply security and cost visibility
Net profit surge of 189% in Q3 FY26 reflects significant operational improvement despite challenging global environment
Strong market position in specialty chemicals provides competitive moat in high-value NCB segment
Named Competitors
Specialty Chemicals — Global specialty chemicals and dyes